Abstract
Rofecoxib (Vioxx) ought to be allowed back on the market, concludes Health Canada's Expert Advisory Panel on the Safety of COX-2 Selective Non-steroidal Anti-Inflammatory Drugs (NSAIDs). After Merck & Co. withdrew rofecoxib from the world marketplace on Sept. 30, 2004 ( CMAJ 2004;171[9]:1027-8),
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
